Advertisement

Hereditary Breast and Ovarian Cancer

An Updated Primer for OB/GYNs

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2020.
        CA Cancer J Clin. 2020; 70: 7-30
        • American Cancer Society
        Breast Cancer Facts & Figures 2017-2018.
        (Available at:) (Accessed 2/5/21, 2021)
        • Rubinstein W.
        The genetics of breast cancer.
        Blackwell Science, Malden, MA2001
        • Norquist B.M.
        • Harrell M.I.
        • Brady M.F.
        • et al.
        Inherited Mutations in Women With Ovarian Carcinoma.
        JAMA Oncol. 2016; 2: 482-490
        • Richards S.
        • Aziz N.
        • Bale S.
        • et al.
        Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
        Genet Med. 2015; 17: 405-424
        • Harrison S.M.
        • Biesecker L.G.
        • Rehm H.L.
        Overview of Specifications to the ACMG/AMP Variant Interpretation Guidelines.
        Curr Protoc Hum Genet. 2019; 103: e93
        • Kurian A.W.
        BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications.
        Curr Opin Obstet Gynecol. 2010; 22: 72-78
        • Walsh T.
        • Casadei S.
        • Lee M.K.
        • et al.
        Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
        Proc Natl Acad Sci U S A. 2011; 108: 18032-18037
        • Miki Y.
        • Swensen J.
        • Shattuck-Eidens D.
        • et al.
        A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
        Science. 1994; 266: 66-71
        • Wooster R.
        • Bignell G.
        • Lancaster J.
        • et al.
        Identification of the breast cancer susceptibility gene BRCA2.
        Nature. 1995; 378: 789-792
        • Nelson H.D.
        • Huffman L.H.
        • Fu R.
        • et al.
        Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2005; 143: 362-379
        • Abul-Husn N.S.
        • Soper E.R.
        • Odgis J.A.
        • et al.
        Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.
        Genome Med. 2019; 12: 2
        • Grzymski J.J.
        • Elhanan G.
        • Morales Rosado J.A.
        • et al.
        Population genetic screening efficiently identifies carriers of autosomal dominant diseases.
        Nat Med. 2020; 26: 1235-1239
        • Manickam K.
        • Buchanan A.H.
        • Schwartz M.L.B.
        • et al.
        Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants.
        JAMA Netw Open. 2018; 1: e182140
        • Moyer V.A.
        Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2014; 160: 271-281
        • Felix G.E.S.
        • Zheng Y.
        • Olopade O.I.
        Mutations in context: implications of BRCA testing in diverse populations.
        Fam Cancer. 2018; 17: 471-483
        • Bylstra Y.
        • Lim W.K.
        • Kam S.
        • et al.
        Family history assessment significantly enhances delivery of precision medicine in the genomics era.
        Genome Med. 2021; 13: 3
        • Berliner J.L.
        • Cummings S.A.
        • Boldt Burnett B.
        • et al.
        Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
        J Genet Couns. 2021; 30: 342-360
        • Owens D.K.
        • Davidson K.W.
        • Krist A.H.
        • et al.
        Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
        JAMA. 2019; 322: 652-665
        • Teller P.
        • Hoskins K.F.
        • Zwaagstra A.
        • et al.
        Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
        Ann Surg Oncol. 2010; 17: 240-246
        • Bellcross C.
        Further development and evaluation of a breast/ovarian cancer genetics referral screening tool.
        Genet Med. 2010; 12: 240
        • Bellcross C.
        Approaches to applying breast cancer risk prediction models in clinical practice.
        Comm Oncol. 2009; 8: 373-379
        • Bellcross C.
        • Hermstad A.
        • Tallo C.
        • et al.
        Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST).
        Genet Med. 2019; 21: 181-184
        • Nelson H.D.
        • Pappas M.
        • Cantor A.
        • et al.
        Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
        JAMA. 2019; 322: 666-685
      1. Referenced with permission from the NCCN Guidelines® for Hereditary Breast, Ovarian and Pancreatic Cancer, V.1.2022.
        (All rights reserved. Accessed 11/1/21. Available online at:)
        • Beitsch P.D.
        • Whitworth P.W.
        • Hughes K.
        • et al.
        Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?.
        J Clin Oncol. 2019; 37: 453-460
        • Tung N.
        • Lin N.U.
        • Kidd J.
        • et al.
        Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
        J Clin Oncol. 2016; 34: 1460-1468
        • Buys S.S.
        • Sandbach J.F.
        • Gammon A.
        • et al.
        A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
        Cancer. 2017; 123: 1721-1730
        • Manahan E.R.
        • Kuerer H.M.
        • Sebastian M.
        • et al.
        Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.
        Ann Surg Oncol. 2019; 26: 3025-3031
        • Copur M.S.
        Universal Genetic Testing for All Breast Cancer Patients.
        Oncology (Williston Park). 2019; 33: 683731
        • Barnes D.R.
        • Rookus M.A.
        • McGuffog L.
        • et al.
        Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
        Genet Med. 2020; 22: 1653-1666
        • Palmer J.R.
        • Polley E.C.
        • Hu C.
        • et al.
        Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women.
        J Natl Cancer Inst. 2020; 112: 1213-1221
        • Childers C.P.
        • Childers K.K.
        • Maggard-Gibbons M.
        • et al.
        National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
        J Clin Oncol. 2017; 35: 3800-3806
        • Manchanda R.
        • Blyuss O.
        • Gaba F.
        • et al.
        Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.
        J Med Genet. 2018; 55: 538-545
        • Chai X.
        • Friebel T.M.
        • Singer C.F.
        • et al.
        Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
        Breast Cancer Res Treat. 2014; 148: 397-406
        • Evans O.
        • Manchanda R.
        Population-based Genetic Testing for Precision Prevention.
        Cancer Prev Res (Phila). 2020; 13: 643-648
        • Gabai-Kapara E.
        • Lahad A.
        • Kaufman B.
        • et al.
        Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
        Proc Natl Acad Sci U S A. 2014; 111: 14205-14210
        • Surgeons ACo
        2020 Standards: Optimal Resources for Cancer Care.
        (Available at:) (Accessed January 15 2021)
        • American Society of Clinical Oncology
        Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
        Obstet Gynecol. 2017; 130: e110-e126
        • Robson M.E.
        • Storm C.D.
        • Weitzel J.
        • et al.
        American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
        J Clin Oncol. 2010; 28: 893-901
        • Hoxhaj I.
        • Tognetto A.
        • Acampora A.
        • et al.
        Core Competencies in Cancer Genomics for Healthcare Professionals: Results From a Systematic Literature Review and a Delphi Process.
        J Cancer Educ. 2021;
        • Cintolo-Gonzalez J.A.
        • Braun D.
        • Blackford A.L.
        • et al.
        Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
        Breast Cancer Res Treat. 2017; 164: 263-284
        • Schrijver L.H.
        • Olsson H.
        • Phillips K.A.
        • et al.
        Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study.
        JNCI Cancer Spectr. 2018; 2: pky023
        • Heemskerk-Gerritsen B.A.M.
        • Jager A.
        • Koppert L.B.
        • et al.
        Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
        Breast Cancer Res Treat. 2019; 177: 723-733
        • Gail M.H.
        • Brinton L.A.
        • Byar D.P.
        • et al.
        Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
        J Natl Cancer Inst. 1989; 81: 1879-1886
        • Amendola L.M.
        • Jarvik G.P.
        • Leo M.C.
        • et al.
        Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.
        Am J Hum Genet. 2016; 98: 1067-1076
        • Balmana J.
        • Digiovanni L.
        • Gaddam P.
        • et al.
        Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing.
        J Clin Oncol. 2016; 34: 4071-4078
        • Slavin T.P.
        • Manjarrez S.
        • Pritchard C.C.
        • et al.
        The effects of genomic germline variant reclassification on clinical cancer care.
        Oncotarget. 2019; 10: 417-423
        • Macklin S.
        • Durand N.
        • Atwal P.
        • et al.
        Observed frequency and challenges of variant reclassification in a hereditary cancer clinic.
        Genet Med. 2018; 20: 346-350
        • van Marcke C.
        • Collard A.
        • Vikkula M.
        • et al.
        Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
        Crit Rev Oncol Hematol. 2018; 132: 138-144
        • Federici G.
        • Soddu S.
        Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers.
        J Exp Clin Cancer Res. 2020; 39: 46
        • Woods N.T.
        • Baskin R.
        • Golubeva V.
        • et al.
        Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance.
        NPJ Genom Med. 2016; 1: 16001
        • Toland A.E.
        • Andreassen P.R.
        DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
        J Med Genet. 2017; 54: 721-731
        • Lyra Jr., P.C.M.
        • Nepomuceno T.C.
        • de Souza M.L.M.
        • et al.
        Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
        Genet Med. 2021; 23: 306-315
        • Domchek S.M.
        • Friebel T.M.
        • Singer C.F.
        • et al.
        Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
        JAMA : J Am Med Assoc. 2010; 304: 967-975
        • Petrucelli N.
        • Daly M.B.
        • Feldman G.L.
        Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.
        Genet Med. 2010; 12: 245-259
        • Girardi F.
        • Barnes D.R.
        • Barrowdale D.
        • et al.
        Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.
        Genet Med. 2018; 20: 1575-1582
        • Samadder N.J.
        • Riegert-Johnson D.
        • Boardman L.
        • et al.
        Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
        JAMA Oncol. 2020; 7: 230-237
        • Peleg Hasson S.
        • Menes T.
        • Sonnenblick A.
        Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.
        Pharmgenomics Pers Med. 2020; 13: 227-238
        • Siraj A.K.
        • Masoodi T.
        • Bu R.
        • et al.
        Expanding the spectrum of germline variants in cancer.
        Hum Genet. 2017; 136: 1431-1444
        • Easton D.F.
        • Pharoah P.D.
        • Antoniou A.C.
        • et al.
        Gene-panel sequencing and the prediction of breast-cancer risk.
        N Engl J Med. 2015; 372: 2243-2257
        • Slavin T.P.
        • Maxwell K.N.
        • Lilyquist J.
        • et al.
        The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.
        NPJ Breast Cancer. 2017; 3: 22
        • Idos G.F.K.A.
        • Ricker C.
        • Shufean M.A.
        • et al.
        Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk.
        JCO Precision Oncology. 2019; 3: 1-12
        • Landrith T.
        • Li B.
        • Cass A.A.
        • et al.
        Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes.
        NPJ Precis Oncol. 2020; 4: 4
        • Forman A.
        • Sotelo J.
        Tumor-Based Genetic Testing and Familial Cancer Risk.
        Cold Spring Harb Perspect Med. 2020; 10: a036590
        • DeLeonardis K.
        • Hogan L.
        • Cannistra S.A.
        • et al.
        When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?.
        J Oncol Pract. 2019; 15: 465-473
        • Sokol E.S.
        • Pavlick D.
        • Khiabanian H.
        • et al.
        Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
        JCO Precision Oncol. 2020; : 442-465
        • McDaniels B.A.
        • Hianik R.S.
        • Bellcross C.
        • et al.
        The Impact of Genetic Counseling Educational Tools on Patients' Knowledge of Molecular Testing Terminology.
        J Cancer Educ. 2020; 35: 864-870
        • Wacholder S.
        • Hartge P.
        • Prentice R.
        • et al.
        Performance of common genetic variants in breast-cancer risk models.
        N Engl J Med. 2010; 362: 986-993
        • Tandy-Connor S.
        • Guiltinan J.
        • Krempely K.
        • et al.
        False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.
        Genet Med. 2018; 20: 1515-1521
        • Konstantinopoulos P.A.
        • Norquist B.
        • Lacchetti C.
        • et al.
        Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
        J Clin Oncol. 2020; 38: 1222-1245
        • Chen J.
        • Bae E.
        • Zhang L.
        • et al.
        Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis.
        JNCI Cancer Spectr. 2020; 4: pkaa029
        • Lewis C.M.
        • Vassos E.
        Polygenic risk scores: from research tools to clinical instruments.
        Genome Med. 2020; 12: 44
        • Janssens A.
        Validity of polygenic risk scores: are we measuring what we think we are?.
        Hum Mol Genet. 2019; 28: R143-R150
        • Weitzel J.N.
        • Blazer K.R.
        • Macdonald D.J.
        • et al.
        Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.
        CA Cancer J Clin. 2011; 61: 327-359
        • Brandt A.
        • Bermejo J.L.
        • Sundquist J.
        • et al.
        Age of onset in familial cancer.
        Ann Oncol. 2008; 19: 2084-2088
        • Lowstuter K.J.
        • Sand S.
        • Blazer K.R.
        • et al.
        Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians.
        Genet Med. 2008; 10: 691-698
        • Willis A.M.
        • Smith S.K.
        • Meiser B.
        • et al.
        Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review.
        Clin Genet. 2017; 92: 121-133
        • Kne A.
        • Zierhut H.
        • Baldinger S.
        • et al.
        Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter.
        J Genet Couns. 2017; 26: 697-715
        • Suter S.M.
        GINA at 10 years: the battle over 'genetic information' continues in court.
        J L Biosci. 2018; 5: 495-526
        • Hall J.P.
        • Moore J.M.
        The Affordable Care Act's pre-existing condition insurance plan: enrollment, costs, and lessons for reform.
        Issue Brief (Commonw Fund). 2012; 24: 1-13
        • Lombardi L.
        • Bramanti S.M.
        • Babore A.
        • et al.
        Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature.
        Support Care Cancer. 2019; 27: 3647-3656
        • Hamilton J.G.
        • Lobel M.
        • Moyer A.
        Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review.
        Health Psychol. 2009; 28: 510-518
        • Ringwald J.
        • Wochnowski C.
        • Bosse K.
        • et al.
        Psychological Distress, Anxiety, and Depression of Cancer-Affected BRCA1/2 Mutation Carriers: a Systematic Review.
        J Genet Couns. 2016; 25: 880-891
        • Lynch H.T.
        • Snyder C.
        • Lynch J.F.
        • et al.
        Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families.
        Cancer Genet Cytogenet. 2006; 165: 91-97
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • et al.
        Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
        JAMA. 2017; 317: 2402-2416
        • Chen S.
        • Iversen E.S.
        • Friebel T.
        • et al.
        Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
        J Clin Oncol. 2006; 24: 863-871
        • Begg C.B.
        • Haile R.W.
        • Borg A.
        • et al.
        Variation of breast cancer risk among BRCA1/2 carriers.
        JAMA. 2008; 299: 194-201
        • Evans D.G.
        • Gaarenstroom K.N.
        • Stirling D.
        • et al.
        Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
        J Med Genet. 2009; 46: 593-597
        • Mavaddat N.
        • Peock S.
        • Frost D.
        • et al.
        Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
        J Natl Cancer Inst. 2013; 105: 812-822
        • Metcalfe K.
        • Gershman S.
        • Lynch H.T.
        • et al.
        Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
        Br J Cancer. 2011; 104: 1384-1392
        • Menes T.S.
        • Terry M.B.
        • Goldgar D.
        • et al.
        Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
        Breast Cancer Res Treat. 2015; 151: 653-660
        • Kotsopoulos J.
        • Lubinski J.
        • Lynch H.T.
        • et al.
        Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
        Breast Cancer Res Treat. 2019; 175: 443-449
        • van der Kolk D.M.
        • de Bock G.H.
        • Leegte B.K.
        • et al.
        Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
        Breast Cancer Res Treat. 2010; 124: 643-651
        • Peterlongo P.
        • Chang-Claude J.
        • Moysich K.B.
        • et al.
        Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
        Cancer Epidemiol Biomarkers Prev. 2015; 24: 308-316
        • Milne R.L.
        • Antoniou A.C.
        Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
        Endocr Relat Cancer. 2016; 23: T69-T84
        • Lesueur F.
        • Mebirouk N.
        • Jiao Y.
        • et al.
        GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.
        Front Oncol. 2018; 8: 490
        • Metcalfe K.
        • Lubinski J.
        • Lynch H.T.
        • et al.
        Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
        J Natl Cancer Inst. 2010; 102: 1874-1878
        • van Erkelens A.
        • Derks L.
        • Sie A.S.
        • et al.
        Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age.
        J Genet Couns. 2017; 26: 785-791
        • Huber D.
        • Seitz S.
        • Kast K.
        • et al.
        Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.
        Arch Gynecol Obstet. 2020; 301: 875-884
        • Mavaddat N.
        • Barrowdale D.
        • Andrulis I.L.
        • et al.
        Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
        Cancer Epidemiol Biomarkers Prev. 2012; 21: 134-147
        • Hodgson A.
        • Turashvili G.
        Pathology of Hereditary Breast and Ovarian Cancer.
        Front Oncol. 2020; 10: 531790
        • Couch F.J.
        • Hart S.N.
        • Sharma P.
        • et al.
        Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
        J Clin Oncol. 2015; 33: 304-311
        • Long K.C.
        • Kauff N.D.
        Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.
        Curr Opin Oncol. 2011; 23: 526-530
        • Vicus D.
        • Finch A.
        • Cass I.
        • et al.
        Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
        Gynecol Oncol. 2010; 118: 299-302
        • Soong T.R.
        • Howitt B.E.
        • Miron A.
        • et al.
        Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
        J Pathol. 2018; 246: 344-351
        • Baretta Z.
        • Mocellin S.
        • Goldin E.
        • et al.
        Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
        Medicine (Baltimore). 2016; 95: e4975
        • Zhu Y.
        • Wu J.
        • Zhang C.
        • et al.
        BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
        Oncotarget. 2016; 7: 70113-70127
        • Copson E.R.
        • Maishman T.C.
        • Tapper W.J.
        • et al.
        Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
        Lancet Oncol. 2018; 19: 169-180
        • Pogoda K.
        • Niwinska A.
        • Sarnowska E.
        • et al.
        Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis.
        J Oncol. 2020; 2020: 8545643
        • Vocka M.
        • Zimovjanova M.
        • Bielcikova Z.
        • et al.
        Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.
        Cancers (Basel). 2019; 11: 738
        • Muranen T.A.
        • Khan S.
        • Fagerholm R.
        • et al.
        Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer.
        NPJ Breast Cancer. 2020; 6: 44
        • Bolton K.L.
        • Chenevix-Trench G.
        • Goh C.
        • et al.
        Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
        JAMA : J Am Med Assoc. 2012; 307: 382-390
        • Synowiec A.
        • Wcislo G.
        • Bodnar L.
        • et al.
        Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.
        Hered Cancer Clin Pract. 2016; 14: 1
        • Harter P.
        • Johnson T.
        • Berton-Rigaud D.
        • et al.
        BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
        Gynecol Oncol. 2016; 140: 443-449
        • Chen P.
        • Huhtinen K.
        • Kaipio K.
        • et al.
        Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
        Cancer Res. 2015; 75: 2987-2998
        • Sabatier R.
        • Lavit E.
        • Moretta J.
        • et al.
        Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
        Fam Cancer. 2016; 15: 497-506
        • Zhong Q.
        • Peng H.L.
        • Zhao X.
        • et al.
        Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
        Clin Cancer Res. 2015; 21: 211-220
        • Robson M.
        • Im S.A.
        • Senkus E.
        • et al.
        Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
        N Engl J Med. 2017; 377: 523-533
        • Lavie O.
        • Chetrit A.
        • Novikov I.
        • et al.
        National Israeli Study of Ovarian C. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
        Gynecol Oncol. 2019; 153: 320-325
        • Chung A.
        • Huynh K.
        • Lawrence C.
        • et al.
        Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients.
        Ann Surg Oncol. 2012; 19: 2600-2606
        • Chiba A.
        • Hoskin T.L.
        • Hallberg E.J.
        • et al.
        Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for brca1/brca2 mutation carriers with breast cancer.
        Ann Surg Oncol. 2016; 23: 3232-3238
        • Wei G.K.A.
        • Lee M.C.
        • Wang X.
        Influential factors on risk reduction mastectomy in a high-risk breast cancer population with genetic predispositions.
        Clin Breast Cancer. 2021; 21: e427-e433
        • Yip C.H.
        • Newman L.A.
        American society of clinical oncology, american society for radiation oncology, and society of surgical oncology guideline for management of hereditary breast cancer.
        JAMA Surg. 2021; 156: 284-285
        • Samadder N.J.
        • Giridhar K.V.
        • Baffy N.
        • et al.
        Hereditary cancer syndromesda primer on diagnosis and management, part 1: breast-ovarian cancer syndromes.
        Mayo Clin Proc. 2019; 94: 1084-1098
        • Moore K.
        • Colombo N.
        • Scambia G.
        • et al.
        Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.
        N Engl J Med. 2018; 379: 2495-2505
        • Tomao F.
        • Boccia S.M.
        • Sassu C.M.
        • et al.
        First-line treatment with olaparib for early stage brca-positive ovarian cancer: may it be possible? hypothesis potentially generating a line of research.
        Cancer Manag Res. 2020; 12: 5479-5489
        • Cott Chubiz J.E.
        • Lee J.M.
        • Gilmore M.E.
        • et al.
        Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
        Cancer. 2013; 119: 1266-1276
        • Saslow D.
        • Boetes C.
        • Burke W.
        • et al.
        American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
        CA Cancer J Clin. 2007; 57: 75-89
        • Warner E.
        • Hill K.
        • Causer P.
        • et al.
        Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.
        J Clin Oncol. 2011; 29: 1664-1669
        • Passaperuma K.
        • Warner E.
        • Causer P.A.
        • et al.
        Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.
        Br J Cancer. 2012; 107: 24-30
        • Rebbeck T.R.
        • Friebel T.
        • Lynch H.T.
        • et al.
        Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
        J Clin Oncol. 2004; 22: 1055-1062
        • De Felice F.
        • Marchetti C.
        • Musella A.
        • et al.
        Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.
        Ann Surg Oncol. 2015; 22: 2876-2880
        • Metcalfe K.A.
        • Birenbaum-Carmeli D.
        • Lubinski J.
        • et al.
        International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
        Int J Cancer. 2008; 122: 2017-2022
        • Giannakeas V.
        • Narod S.A.
        The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
        Breast Cancer Res Treat. 2018; 167: 263-267
        • McGee J.
        • Giannakeas V.
        • Karlan B.
        • et al.
        Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?.
        Gynecol Oncol. 2017; 145: 346-351
        • Phillips K.A.
        • Milne R.L.
        • Bassett J.K.
        • et al.
        Tamoxifen and contralateral breast cancer (CBC) risk for BRCA1 and BRCA2 mutation carriers: An updated analysis of data from the Kathleen Cuningham Foundation consortium for research into familial breast cancer, the International BRCA1 and BRCA2 Carrier cohort study and the breast cancer family registry.
        Cancer Res. 2018; 78 (P3-P10-01)
        • Singer C.F.
        Nonsurgical Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers.
        Breast Care. 2021; : 1-5
        • Hartmann L.C.
        • Sellers T.A.
        • Schaid D.J.
        • et al.
        Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
        J Natl Cancer Inst. 2001; 93: 1633-1637
        • Campbell A.M.
        • Morris M.
        • Gallagher R.
        • et al.
        Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
        BMJ Open. 2018; 8: e023115
        • Pujol P.
        • Roca L.
        • Lortholary A.
        • et al.
        Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial.
        J Clin Oncol. 2020; 38: 1534
        • Woodward E.R.
        • Sleightholme H.V.
        • Considine A.M.
        • et al.
        Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective.
        BJOG : Int J Obstet Gynaecol. 2007; 114: 1500-1509
        • van der Velde N.M.
        • Mourits M.J.
        • Arts H.J.
        • et al.
        Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?.
        Int J Cancer. 2009; 124: 919-923
        • Eleje G.U.
        • Eke A.C.
        • Ezebialu I.U.
        • et al.
        Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
        Cochrane Database Syst Rev. 2018; 8: CD012464
        • Rebbeck T.R.
        • Kauff N.D.
        • Domchek S.M.
        Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
        J Natl Cancer Inst. 2009; 101: 80-87
        • Finch A.P.
        • Lubinski J.
        • Moller P.
        • et al.
        Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
        J Clin Oncol. 2014; 32: 1547-1553
        • Xiao Y.L.
        • Wang K.
        • Liu Q.
        • et al.
        Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer: meta-analysis and systematic review.
        Clin Breast Cancer. 2019; 19: e48-e65
        • Marchetti C.
        • De Felice F.
        • Boccia S.
        • et al.
        Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
        Crit Rev Oncol Hematol. 2018; 132: 111-115
        • Gasparri M.L.
        • Taghavi K.
        • Fiacco E.
        • et al.
        Risk-reducing bilateral salpingo-oophorectomy for brca mutation carriers and hormonal replacement therapy: if it should rain, better a drizzle than a storm.
        Medicina (Kaunas). 2019; 55: 415
        • Tai Y.C.
        • Domchek S.
        • Parmigiani G.
        • et al.
        Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
        J Natl Cancer Inst. 2007; 99: 1811-1814
        • Pritzlaff M.
        • Summerour P.
        • McFarland R.
        • et al.
        Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
        Breast Cancer Res Treat. 2017; 161: 575-586
        • Scarpitta R.
        • Zanna I.
        • Aretini P.
        • et al.
        Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing.
        Breast Cancer Res Treat. 2019; 178: 557-564
        • Fostira F.
        • Saloustros E.
        • Apostolou P.
        • et al.
        Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
        Breast Cancer Res Treat. 2018; 169: 105-113
        • Shindo K.
        • Yu J.
        • Suenaga M.
        • et al.
        Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma.
        J Clin Oncol. 2017; 35: 3382-3390
        • Pilarski R.
        The role of BRCA testing in hereditary pancreatic and prostate cancer families.
        Am Soc Clin Oncol Educ Book. 2019; 39: 79-86
        • Rainone M.
        • Singh I.
        • Salo-Mullen E.E.
        • et al.
        An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review.
        JAMA Oncol. 2020; 6: 764-771
        • Lowery M.A.
        • Wong W.
        • Jordan E.J.
        • et al.
        Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms.
        J Natl Cancer Inst. 2018; 110: 1067-1074
        • Nyberg T.
        • Frost D.
        • Barrowdale D.
        • et al.
        Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
        Eur Urol. 2020; 77: 24-35
        • Nicolosi P.
        • Ledet E.
        • Yang S.
        • et al.
        Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines.
        JAMA Oncol. 2019; 5: 523-528
        • Johansson P.A.
        • Nathan V.
        • Bourke L.M.
        • et al.
        Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
        Melanoma Res. 2019; 29: 483-490